Quarterly Research Update
Imperial Peptides Q2 2026 Update: April–June
A quarterly look at the latest Imperial Peptides catalogue additions, batch testing updates, COA releases and operational improvements from Q2 2026.
Expanding the Research Catalogue
During Q2, Imperial Peptides expanded its research-use-only peptide catalogue with four new additions. These products were introduced in response to growing demand from UK-based researchers seeking clearly presented, batch-documented research peptides.
KPV 10mg
New Q2 catalogue addition
SS-31 10mg
New Q2 catalogue addition
DSIP 10mg
New Q2 catalogue addition
Epitalon 10mg
New Q2 catalogue additionThese additions strengthen the wider Imperial Peptides catalogue and support our continued focus on becoming a trusted UK supplier of research-use-only peptides.
New Batch Releases & COA Updates
Batch documentation remained a key focus throughout Q2. Several new batches were released with updated Certificates of Analysis, supporting greater transparency for researchers reviewing products before ordering.
| Product | Batch Code |
|---|---|
| BPC-157 10mg | BPC10-03/28 |
| GHK-Cu 50mg | GHK50-03/28 |
| Ipamorelin 5mg | IPA5-04/28 |
| CJC-1295 No DAC 5mg | CND5-04/28 |
| GHK-Cu 50mg | GHK50-05/28 |
All available batch-specific Certificates of Analysis can be viewed through the Imperial Peptides COA library.
View COAsGHK50-03/28 Batch Advisory
In Q2, we published a dedicated advisory for batch GHK50-03/28. Where a batch requires additional explanation, our position is simple: communicate clearly, publish the information and allow researchers to make informed decisions.
The advisory reflects our wider approach to transparency. Batch information should be easy to access, easy to understand and clearly linked to the relevant product documentation.
Supply Chain Update: Bacteriostatic Water
Throughout Q2, the wider research supply chain continued to experience disruption. Due to an ongoing shortage of Hospira Bacteriostatic Water, alongside recent regulatory and customs changes affecting imports, our previous manufacturing partners were no longer able to maintain supply.
Rather than compromise on quality or product traceability, we secured a new manufacturing partner to ensure continuity of supply. While this transition has resulted in longer lead times and increased sourcing costs, it allows us to maintain the standards our customers expect.
Why this matters: Every change within our supply chain is evaluated against our quality standards. We would rather delay supply than introduce products that do not meet our expectations for documentation, traceability and manufacturing consistency.
As the transition completes, pricing will be adjusted to reflect the higher sourcing and import costs associated with the new supply chain. These changes have been implemented to protect long-term availability while continuing our commitment to batch verification, quality control and product traceability.
We appreciate the patience and understanding shown by our customers throughout this period and look forward to restoring consistent availability in the coming months.
Protecting Customers From Fake Websites
Brand protection was another important operational focus during Q2. As Imperial Peptides has grown, we have seen attempts by unofficial websites to imitate or trade off the brand name.
During the quarter, further action was taken to remove fake websites and help customers identify the official Imperial Peptides UK channels. This is especially important in the research peptide market, where documentation, traceability and legitimate customer support matter.
Customers should always order through the official Imperial Peptides website and avoid copycat domains, impersonation attempts or unofficial sellers.
Continued Focus on Trust, Testing & Transparency
Q2 was not only about expanding the catalogue. It was also about strengthening the foundations behind Imperial Peptides: clearer product pages, updated batch documentation, public COA access and direct communication around important operational updates.
Researchers want more than a product listing. They want consistency, evidence and a supplier that takes documentation seriously. That remains central to how Imperial Peptides is being built.
Looking Ahead to Q3
As we move into Q3, our focus remains on responsible catalogue growth, continued third-party testing, improved research education and further protection of the Imperial Peptides brand.
Our commitment is to keep building Imperial Peptides as a trusted UK research-use-only peptide supplier through clear documentation, independent testing and a transparent customer experience.
